Evommune, INC 8-K filings

Evommune, Inc. has dosed the first patient in its Phase 2b clinical trial for EVO756, an MRGPRX2 inhibitor, for migraine prophylaxis, with top-line data expected in 2027.

Evommune, Inc. announced that its EVO756 Phase 2b trial for chronic spontaneous urticaria did not meet its primary endpoint, leading to the discontinuation of development for this indication.

Evommune, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Evommune announced its first quarter 2026 financial results, highlighting progress in its EVO756 and EVO301 clinical programs with key data readouts expected throughout 2026.

Evommune, Inc. hosted a webcast on April 13, 2026, discussing the migraine treatment landscape and the role of MRGPRX2 inhibition, with a focus on their drug candidate EVO756.

Evommune, Inc. announced positive Phase 2a data for EVO301 in atopic dermatitis, reported full-year 2025 financial results, and closed a $125 million private placement extending its cash runway through 2028.

Evommune, a clinical-stage biotech, announced a private placement of common stock raising approximately $125 million to fund clinical development and general corporate purposes.

Evommune, Inc. announced positive top-line data from its Phase 2a proof-of-concept trial of EVO301 in moderate-to-severe atopic dermatitis, meeting its primary efficacy endpoint.